全文获取类型
收费全文 | 216092篇 |
免费 | 4006篇 |
国内免费 | 163篇 |
专业分类
耳鼻咽喉 | 1622篇 |
儿科学 | 8001篇 |
妇产科学 | 3605篇 |
基础医学 | 21353篇 |
口腔科学 | 2135篇 |
临床医学 | 16569篇 |
内科学 | 40064篇 |
皮肤病学 | 1354篇 |
神经病学 | 20433篇 |
特种医学 | 10513篇 |
外科学 | 35784篇 |
综合类 | 2680篇 |
一般理论 | 82篇 |
预防医学 | 21112篇 |
眼科学 | 3864篇 |
药学 | 11550篇 |
中国医学 | 663篇 |
肿瘤学 | 18877篇 |
出版年
2023年 | 356篇 |
2022年 | 677篇 |
2021年 | 1594篇 |
2020年 | 796篇 |
2019年 | 1334篇 |
2018年 | 23295篇 |
2017年 | 18285篇 |
2016年 | 20500篇 |
2015年 | 2161篇 |
2014年 | 2539篇 |
2013年 | 2841篇 |
2012年 | 10388篇 |
2011年 | 24334篇 |
2010年 | 20573篇 |
2009年 | 13134篇 |
2008年 | 22167篇 |
2007年 | 24292篇 |
2006年 | 3168篇 |
2005年 | 4624篇 |
2004年 | 5782篇 |
2003年 | 6342篇 |
2002年 | 4341篇 |
2001年 | 537篇 |
2000年 | 627篇 |
1999年 | 434篇 |
1998年 | 556篇 |
1997年 | 524篇 |
1996年 | 327篇 |
1995年 | 334篇 |
1994年 | 264篇 |
1993年 | 226篇 |
1992年 | 201篇 |
1991年 | 241篇 |
1990年 | 245篇 |
1989年 | 180篇 |
1988年 | 133篇 |
1987年 | 145篇 |
1986年 | 120篇 |
1985年 | 121篇 |
1984年 | 115篇 |
1983年 | 124篇 |
1982年 | 140篇 |
1981年 | 85篇 |
1980年 | 109篇 |
1979年 | 58篇 |
1978年 | 57篇 |
1977年 | 57篇 |
1974年 | 63篇 |
1938年 | 60篇 |
1932年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Leslee J. Shaw Romalisa Miranda-Peats Piotr Slomka John Friedman Sean W. Hayes Daniel S. Berman Gary V. Heller Marcin Dada William E. Boden Paul Casperson Robert A. O’Rourke Ronald Schwartz William S. Weintraub David J. Maron Spencer King Koon Teo Pamela Hartigan 《Journal of nuclear cardiology》2006,13(5):685-698
Background Stress gated myocardial perfusion single photon emission computed tomography (gSPECT) is increasingly used before and after
intercurrent therapeutic intervention and is the basis for ongoing evaluation in the Department of Veterans Affairs clinical
outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial.
Methods and Results The COURAGE trial is a North American multicenter randomized clinical trial that enrolled 2287 patients to aggressive medical
therapy vs percutaneous coronary intervention plus aggressive medical therapy. Three COURAGE nuclear substudies have been
designed. The goals of substudy 0 are to examine the diagnostic accuracy of the extent and severity of inducible ischemia
at baseline in COURAGE patients compared with patient symptoms and quantitative coronary angiography and to explore the relationship
between inducible ischemia and the benefit from revascularization when added to medical therapy. Substudy 1 will correlate
the extent and severity of provocative ischemia with the frequency, quality, and instability of recurrent symptoms in postcatheterization
patients. Substudy 2 (n _ 300) will examine the usefulness of sequential gSPECT monitoring 6 to 18 months after therapeutic
intervention. Together, these nuclear substudies will evaluate the role of gSPECT to determine the effectiveness of aggressive
risk-factor modifications, lifestyle interventions, and anti-ischemic medical therapies with or without revascularization
in reducing patients’ ischemic burdens.
Conclusions The unfolding of evidence on the application of gSPECT in trials such as COURAGE defines a new era for nuclear cardiology.
We hope the evidence that emerges from the COURAGE trial will further establish the role of nuclear imaging in the evidence-based
management of patients with stable coronary disease.
The COURAGE trial was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research
and Development in collaboration with the Canadian Institutes of Health Research. Unrestricted research grants were obtained
from Merck & Co; Pfizer Pharmaceuticals; Bristol-Myers Squibb Medical Imaging; Astellas Pharma; Kos Pharmaceuticals; Data
Scope; Astra Zeneca Pharmaceuticals; Astra-Zeneca-Canada; Schering-Plough Coorporation, Ltd; Sanofi-Aventis, Inc; First Horizon;
and GE Healthcare. All industrial funding for this trial was directed through the Department of Veterans Affairs. Additional
funding for this substudy was provided by grants to the Department of Veterans Affairs and Canadian Institutes of Health Research
from Astellas Pharma and Bristol-Myers-Squibb Medical Imaging. 相似文献
72.
Edward M Messing Judith Manola George Wilding Kathleen Propert Jonathan Fleischmann E David Crawford J Edson Pontes Richard Hahn Donald Trump 《Journal of clinical oncology》2003,21(7):1214-1222
PURPOSE: To evaluate the role of adjuvant interferon alfa after complete resection of locally extensive renal cell carcinoma. PATIENTS AND METHODS: A total of 283 eligible patients with pT3-4a and/or node-positive disease were randomly assigned after radical nephrectomy and lymphadenectomy to observation or to interferon alfa-NL (Wellferon, Burroughs-Wellcome, Research Park, NC) given daily for 5 days every 3 weeks for up to 12 cycles. Patients were stratified on the basis of pathologic stage. Patients remained on treatment until documented recurrence, excessive toxicity, or patient/physician preference deemed removal appropriate. RESULTS: At median follow-up of 10.4 years, median survival was 7.4 years in the observation arm and 5.1 year in the treatment arm (log-rank P =.09). Median recurrence-free survival was 3.0 years in the observation arm and 2.2 years in the interferon arm (P =.33). Performance status (P =.003), nodal status (N2 v N0, P <.0001), and tumor stage (P =.0002) were significant prognostic factors in multivariate analysis. A proportional hazards model examining the effects of treatment arm and time to recurrence on survival after recurrence among patients who recurred found that random assignment to interferon treatment (P =.009) and shorter time to recurrence (P <.0001) were independent predictors of shorter survival after recurrence. Although no lethal toxicities were observed, severe (grade 4) toxicities including neutropenia, myalgia, fatigue, depression, and other neurologic toxicities occurred in 11.4% of those randomly assigned to interferon treatment. CONCLUSION: Adjuvant treatment with interferon did not contribute to survival or relapse-free survival in this group of patients. 相似文献
73.
74.
Sergio Barroilhet Adrián Cano-Prous Salvador Cervera-Enguix Maria João Forjaz Francisco Guillén-Grima 《Social psychiatry and psychiatric epidemiology》2009,44(12):1051-1065
Introduction
This paper presents the results of a study on the psychometric properties of an authorized Spanish version of the McMaster Family Assessment Device, a self-report measure of family functioning. 相似文献75.
76.
77.
Introduction
Although ependymoma is the third most common pediatric brain tumor, we know little about the genetic/epigenetic basis of its initiation, maintenance, or progression. This is due in part to the heterogeneity of the disease, as well as the small sample size of the cohorts analyzed in most studies. 相似文献78.
Peter Angelos 《World journal of surgery》2009,33(4):609-611
79.
Kentaroh Miyoshi Minoru Naito Tsuyoshi Ueno Shinji Hato Hideo Ino 《General thoracic and cardiovascular surgery》2009,57(11):629-632
A benign esophageal leiomyoma with abnormally increased fluorine-18-fluorodeoxyglucose uptake on positron emission tomography
(PET) was resected thoracoscopically. The tumor, of which the maximum standardized uptake value of the lesion was 4.7, was
well defined and 38 mm in diameter. Neither mitotic activity nor degeneration was found histologically; and immunoreactivity
for CD34, CD117, MIB-1, and glucose transporter-1 was negative immunohistochemically. A diagnosis of gastrointestinal stromal
tumor was ruled out by an oncogenic kinase gene mutation study. This case cautions against PET-dependent evaluation for malignant
potential of esophageal submucosal tumors. 相似文献
80.